Literature DB >> 16432144

Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition.

Valerie Askanas1, W King Engel.   

Abstract

Sporadic inclusion-body myositis (s-IBM), the most common muscle disease of older persons, is of unknown cause and there is no successful treatment. We summarize our most recent findings, which provide a better understanding of the steps in the pathogenetic cascade. We suggest that s-IBM is primarily a myodegenerative disease. Intriguing are the phenotypic similarities between s-IBM muscle fibers and the brains of Alzheimer disease, the most common neurodegenerative disease of older persons. In s-IBM, abnormal accumulation of the amyloid-beta (Abeta) precursor protein and its proteolytic fragment, Abeta, associated with the aging intracellular milieu of the muscle fiber, appear to be key upstream pathogenic events. We propose that the identified abnormal accumulation, misfolding, and aggregation of proteins, perhaps provoked by the aging milieu and aggravated by the oxidative stress, lead to the s-IBM-specific vacuolar degeneration and atrophy of muscle fibers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432144     DOI: 10.1212/01.wnl.0000192128.13875.1e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  49 in total

1.  ANT1 is reduced in sporadic inclusion body myositis.

Authors:  E Barca; M Aguennouz; A Mazzeo; S Messina; A Toscano; G L Vita; S Portaro; D Parisi; C Rodolico
Journal:  Neurol Sci       Date:  2012-02-21       Impact factor: 3.307

Review 2.  Update on Inclusion Body Myositis.

Authors:  Duaa Jabari; V V Vedanarayanan; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Rheumatol Rep       Date:  2018-06-28       Impact factor: 4.592

Review 3.  Prion-like mechanisms in neurodegenerative diseases.

Authors:  Bess Frost; Marc I Diamond
Journal:  Nat Rev Neurosci       Date:  2009-12-23       Impact factor: 34.870

4.  The protein oxidation repair enzyme methionine sulfoxide reductase a modulates Aβ aggregation and toxicity in vivo.

Authors:  Alicia N Minniti; Macarena S Arrazola; Marcela Bravo-Zehnder; Francisca Ramos; Nibaldo C Inestrosa; Rebeca Aldunate
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

5.  Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis.

Authors:  Bumsup Kwon; Pravir Kumar; Han-Kyu Lee; Ling Zeng; Kenneth Walsh; Qinghao Fu; Amey Barakat; Henry W Querfurth
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

Review 6.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 7.  Expression and function of APP and its metabolites outside the central nervous system.

Authors:  Kendra L Puig; Colin K Combs
Journal:  Exp Gerontol       Date:  2012-07-27       Impact factor: 4.032

8.  Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model.

Authors:  May Christine V Malicdan; Satoru Noguchi; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

Review 9.  The expanding realm of prion phenomena in neurodegenerative disease.

Authors:  Bess Frost; Marc I Diamond
Journal:  Prion       Date:  2009-04-16       Impact factor: 3.931

10.  Intracellular amyloid formation in muscle cells of Abeta-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification.

Authors:  Alicia N Minniti; Daniela L Rebolledo; Paula M Grez; Ricardo Fadic; Rebeca Aldunate; Irene Volitakis; Robert A Cherny; Carlos Opazo; Colin Masters; Ashley I Bush; Nibaldo C Inestrosa
Journal:  Mol Neurodegener       Date:  2009-01-06       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.